May 22, 2020 / 12:11 PM / 9 days ago

BRIEF-Xeris Pharmaceuticals Announces Positive Findings Mid-stage Study Of Its Developmental Glucagon

May 22 (Reuters) - Xeris Pharmaceuticals Inc:

* XERIS PHARMACEUTICALS ANNOUNCES POSITIVE FINDINGS FROM THE OUTPATIENT PORTION OF A PHASE 2 PROOF-OF-CONCEPT STUDY OF ITS DEVELOPMENTAL READY-TO-USE (RTU) GLUCAGON IN PATIENTS AT RISK OF POSTPRANDIAL HYPOGLYCEMIA FOLLOWING BARIATRIC SURGERY

* XERIS PHARMACEUTICALS - REBOUND HYPOGLYCEMIA OBSERVED IN PLACEBO ARM WITH ORAL GLUCOSE TABLET USE

* XERIS PHARMACEUTICALS INC - NO REBOUND HYPOGLYCEMIA OBSERVED IN RTU GLUCAGON TREATMENT ARM Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below